Compound ID | 1122

Update compound information

Tigemonam

Synonym(s): SQ 30213

Class: Beta-lactam

Agent Type: Semisynthetic; Small molecule; Direct acting;
Spectrum of activity: Gram-negative
Mechanism of action: Cell wall synthesis inhibitor
Target Pathogen: Active against Gram-negative except Pseudomonas
Description: A monobactam
Institute where first reported: Bristol Myers Squibb
Year first mentioned: 1985
Highest development stage: Approved for veterinary use; Phase 2
Development status: Inactive
Reason dropped: Discontinued in 1994
Chemical structure(s):
Click here for structure editor
Molecular weight: 437.41
Iso. SMILES: CC1([C@@H](C(=O)N1OS(=O)(=O)O)NC(=O)/C(=N\OCC(=O)O)/C2=CSC(=N2)N)C
InChI Key: VAMSVIZLXJOLHZ-QWFSEIHXSA-N
Can. SMILES: CC1(C)[C@@H](C(=O)N1OS(=O)(=O)O)NC(=O)/C(=N\OCC(=O)O)/C2=CSC(=N2)N
InChI: InChI=1S/C12H15N5O9S2/c1-12(2)8(10(21)17(12)26-28(22,23)24)15-9(20)7(16-25-3-6(18)19)5-4-27-11(13)14-5/h4,8H,3H2,1-2H3,(H2,13,14)(H,15,20)(H,18,19)(H,22,23,24)/b16-7-/t8-/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/9576769
Guide to Pharmacology: tigemonam
Citation: https://doi.org/10.1128/aac.32.1.84
Patent: US20140128364A1

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.